The infection control market size was exhibited at USD 227.21 billion in 2024 and is projected to hit around USD 438.67 billion by 2034, growing at a CAGR of 6.8% during the forecast period 2024 to 2034.
The U.S. infection control market size is evaluated at USD 52.83 billion in 2024 and is projected to be worth around USD 102.67 billion by 2034, growing at a CAGR of 6.22% from 2024 to 2034.
North America dominated the infection control market and accounted for the largest revenue share of over 31.0% in 2024. The substantial share captured by this region is due to a good number of strategic collaborations by key companies in the market to widen their infection control capabilities and product portfolio. In addition, increasing efforts by the established companies to widen their presence across this region is responsible for the dominant share captured by North America. For instance, In January 2017, Advanced Sterilization Products launched the STERRAD 100NX System with ALLClear in the U.S. and is planning to expand its footprint into regions such as Europe, Africa, and the Middle East. In 2020, Advance Sterilization Products got 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a 15-minute time result for the STERRAD VELOCITY® Biological Indicator, which is a device used in the STERRAD System. It offers the fastest way to provide instrument sterilization for healthcare professionals.
Asia Pacific is expected to expand at the fastest CAGR of 8.3% over the forecast period from 2024 to 2034, owing to the growing number of outsourcing organizations, growing expenditure on healthcare, and evolving healthcare standards and infrastructure unprecedently across this region. Government organizations are focusing more on improving infection control standards as it is also one of the important factors contributing to the growth of the Asia Pacific region. The increasing trend of outsourcing by established market players in developed economies to companies in the Asia Pacific region also serves as a key growth impelling factor for the market. For instance, the Asia Pacific Society of Infection Control (APSIC) is a voluntary organization working to establish collaborative partnerships to facilitate quality improvement and conduct infection control research to promote cost-efficient practices throughout the Asia Pacific region.
| Report Coverage | Details |
| Market Size in 2025 | USD 242.66 Billion |
| Market Size by 2034 | USD 438.67 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 6.8% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Type, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | 3M; Belimed AG; O&M Halyard or its affiliates.; Getinge Group; ASP; MATACHANA; Sterigenics U.S., LLC – A Sotera Health company; MMM Group; Cantel Medical Corp.; STERIS Corporation; Midmark Corporation.; Medivators Inc.; W&H |
Based on the type, the global infection control market is segmented into equipment, services, and consumables. The consumables segment dominated the market for infection control and accounted for the largest revenue share in 2024. The dominant share captured by consumables is predicted to be a consequence of consistent usage and the short life cycle of these products. Consumables are being extensively incorporated in disinfection, sterilization, and other control procedures and are indispensable parts of the procedures mentioned above, accounting for a larger share. Under consumables, personal protective equipment held a substantial share as of 2024.
Further, the equipment segment is classified as disinfectors and sterilization equipment. Again disinfectors are further segmented into washers, flushes, and endoscope reprocessors. The sterilization equipment is segmented into heat sterilization equipment, low-temperature sterilization equipment, radiation sterilization equipment, filtration sterilization equipment, and liquid sterilization equipment. Also, consumables are segmented into infectious waste disposal, disinfectants, sterilization consumables, personal protective equipment, and others.
Various healthcare organizations are advocating and promoting awareness about the benefits of personal protective equipment, which is anticipated to be responsible for a significant share. For instance, W&H company is working on a hygiene portfolio and added the LEXA PLUS CLASS B sterilizer, a new technologically advanced device for easier reprocessing and infection prevention for dental practice workflow.
Based on type, the services segment is expected to grow at the fastest CAGR during the forecast period. This fastest growth is attributed to the high inclination of market players to reduce overall healthcare expenditure and the utilization of benefits involved. It primarily includes cost advantages, increased efficiency of services, enhanced productivity, and a significantly higher focus on the core areas of development, which are critical to a company’s overall profit and growth. The organizations also strive to promote the adoption through issuing guidelines and recommendations for selection, risk assessment, rational usage, removal, and considerations to reduce the risk of transmission of respiratory pathogens to healthcare workers and other medical staff within a healthcare facility. Further, services are segmented into contract sterilization and infectious waste disposal. The contract sterilization segment is again classified into ethylene oxide sterilization, e-beam sterilization, gamma sterilization, and others.
Based on end use, the global infection control market is segmented into medical device companies, hospitals, pharmaceutical companies, clinical laboratories, and others. The hospital segment dominated the market for infection control and accounted for the largest revenue share of around 41.0% in 2024 and is also expected to grow at the fastest CAGR of 7.4% over the forecast period from 2024 to 2034. The considerable share is majorly a result of the high probability of getting infected on hospital premises by transmitting blood-borne or respiratory pathogens. Hospital-acquired infections require rigorous control as it is one of the major challenges faced by the market. This has urged public health organizations and hospitals to adopt highly effective control systems. Also, as per research published in NCBI, 40% to 60% of hospital infections were estimated to be at surgical sites.
One of the major concerns is the high probability of infection from pathogens such as drug-resistant, blood-borne, and others in the operating room, because of which the need of the market is growing. For instance, frequent usage of urinary catheters poses a high probability of UTIs and may result in catheter-associated (CA)-UTIs. According to data published by the National Center for Biotechnology Information (NCBI), UTIs account for 25% of all bacterial infections. As per the data published in the National Nosocomial Infection Surveillance (NNIS) system report, the most frequently occurring HAI are associated with CA-bacteriuria and catheterization globally, accounting for 40% of HAIs in the U.S. annually. These factors are expected to widen the future growth prospects of the market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the infection control market
By Type
By End-use
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. End use outlook
2.2.3. Regional scope
2.3. Competitive Insights
Chapter 3. Infection Control Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Infection Control Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Infection Control Market: Type Estimates & Trend Analysis
4.1. Infection Control Market: Key Takeaways
4.2. Infection Control Market: Movement & Market Share Analysis, 2024 & 2034
4.3. Equipment
4.3.1. Equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.2. Disinfectors
4.3.2.1. Disinfectors market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.2.2. Washers
4.3.2.2.1. Washers market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.2.3. Flushers
4.3.2.3.1. Flushers market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.2.4. Endoscope reprocessors
4.3.2.4.1. Endoscope reprocessors market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3. Sterilization equipment
4.3.3.1. Sterilization equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3.2. Heat sterilization equipment
4.3.3.2.1. Heat sterilization equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3.3. Low-temperature equipment
4.3.3.3.1. Low-temperature equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3.4. Radiation sterilization equipment
4.3.3.4.1. Radiation sterilization equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3.5. Filtration sterilization equipment
4.3.3.5.1. Filtration sterilization equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.3.6. Liquid sterilization equipment
4.3.3.6.1. Liquid sterilization equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.4. Others
4.3.4.1. Others market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.5. Services
4.3.6. Services market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.7. Contract sterilization
4.3.7.1. Contract sterilization market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.7.2. Ethylene oxide sterilization
4.3.7.2.1. Ethylene oxide sterilization market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.7.3. E-Beam sterilization
4.3.7.3.1. E-Beam sterilization market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.7.4. Gamma sterilization
4.3.7.4.1. Gamma sterilization market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.7.5. Others
4.3.7.5.1. Others market estimates and forecasts, 2021 to 2034 (USD Billion)
4.3.8. Infectious waste disposal
4.3.8.1. Infectious waste disposal market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4. Consumables
4.4.1. Consumables market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4.2. Infectious waste disposal
4.4.2.1. Infectious waste disposal market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4.3. Disinfectants
4.4.3.1. Disinfectants market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4.4. Sterilization consumables
4.4.4.1. Sterilization consumables market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4.5. Personal protective equipment
4.4.5.1. Personal protective equipment market estimates and forecasts, 2021 to 2034 (USD Billion)
4.4.6. Others
4.4.6.1. Others market estimates and forecasts, 2021 to 2034 (USD Billion)
Chapter 5. Infection Control Market: End Use Estimates & Trend Analysis
5.1. Infection Control Market: Key Takeaways
5.2. Infection Control Market: Movement & Market Share Analysis, 2024 & 2034
5.3. Hospitals
5.3.1. Hospitals market estimates and forecasts, 2021 to 2034 (USD Billion)
5.4. Medical Device Companies
5.4.1. Medical devices companies market estimates and forecasts, 2021 to 2034 (USD Billion)
5.5. Clinical Laboratories
5.5.1. Clinical laboratories market estimates and forecasts, 2021 to 2034 (USD Billion)
5.6. Pharmaceutical Companies
5.6.1. Pharmaceutical companies market estimates and forecasts, 2021 to 2034 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts, 2021 to 2034 (USD Billion)
Chapter 6. Infection Control Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Infection Control Market by Region: Key Takeaways
6.3. North America
6.3.1. North America market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. U.S. market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Canada market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4. Europe
6.4.1. Europe market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.2. UK
6.4.2.1. UK market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.3. Germany
6.4.3.1. Germany market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.4. France
6.4.4.1. France market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.5. Italy
6.4.5.1. Italy market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.6. Spain
6.4.6.1. Spain market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Sweden market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Norway market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.4.9. Denmark
6.4.9.1. Denmark market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.2. Japan
6.5.2.1. Japan market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.3. China
6.5.3.1. China market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.4. India
6.5.4.1. India market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.5. Australia
6.5.5.1. Australia market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.6. Thailand
6.5.6.1. Thailand market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.5.7. South Korea
6.5.7.1. South Korea market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.6. Latin America
6.6.1. Latin America market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.6.2. Brazil
6.6.2.1. Brazil market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.6.3. Mexico
6.6.3.1. Mexico market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.6.4. Argentina
6.6.4.1. Argentina market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.7. MEA
6.7.1. MEA market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Saudi Arabia market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.7.3. South Africa
6.7.3.1. South Africa market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.7.4. UAE
6.7.4.1. UAE market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
6.7.5. Kuwait
6.7.5.1. Kuwait market estimates and forecasts, 2021 - 2034 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. 3M
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Belimed AG
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. O&M Halyards or its affiliates.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Getinge
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. ASP
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Sterigenics U.S., LLC - A Sotera Health company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. MMM Group
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Cantel Medical Corp.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. STERIS PLC
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Midmark Corporation.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Medivators Inc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. W&H
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers